Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin-ESHAP vs ESHAP in Relapsed/Refractory Classical Hodgkin's Lymphoma (BRESELIBET)
NCT04378647Phase 2Recruiting
- Sponsor
- GELTAMO
- Start
- Jun 2020
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Classical Hodgkin Lymphoma (cHL), sponsored by GELTAMO. Started Jun 2020; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT04378647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04378647.